Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.54 |
| ▸ | HTR3B | O95264 | 2/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.54 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578099 | 1.00 | MAPK8 (0.54) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31377522 | 0.81 | MAPK8 (0.40) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8102963 | 0.80 | CUL4A (0.51) | MAPK8PTPN1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL169235 | 0.79 | MAPK8 (0.54) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31746758 | 0.79 | MAPK8 (0.54) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13131265 | 0.79 | PTPN2 (0.59) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11418210 | 0.79 | KDM4E (0.49) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL24832295 | 0.78 | IKBKB (0.45) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3496046 | 0.78 | HTR3E (0.40) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30973203 | 0.78 | IKBKB (0.45) | MAPK8HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454900-B | Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer | 蒙彼利埃大学 | 2020-08-07 | — | — | CN | disclosed |
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| CN-110621333-A | Prevention and/or treatment of inflammatory skin diseases | 荷兰联合利华有限公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) | 2018-01-18 | — | — | US | disclosed |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) | 2018-01-18 | — | — | US | disclosed |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) | 2018-01-18 | — | — | US | disclosed |
| WO-2009043934-A1 | IMIDAZO[L,2-α]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIVERSITE DE MONTPELLIER I (FR) | 2009-04-09 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-0743945-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2002-03-06 | — | — | EP | disclosed |
| US-6124287-A | TREATING DEPRESSION | BIOMEDICA FOSCAMA INDUSTRIA CHIMICOFARMACEUTICA S.P.A. (IT) | 2000-09-26 | — | — | US | disclosed |
| EP-0865442-B1 | IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOSCAMA BIOMED CHIM FARMA (IT) | 2000-07-05 | — | — | EP | disclosed |
| EP-0865442-A1 | IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | Biomedica Foscama Industria Chimico-Farmaceutica S.p.A. (IT) | 1998-09-23 | — | — | EP | disclosed |
| US-5741785-A | IMIDAZOLO(1,2-A)QUINOXALINONE COMPOUNDS; ANTIISCHEMIC AGENTS; NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1998-04-21 | — | — | US | disclosed |
| WO-1997019079-A1 | IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1997-05-29 | — | — | WO | disclosed |
| EP-0743945-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021842-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | MAPK8 1826/4885HTR3E 3553/4885HTR3B 3276/4885 |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | MAPK8 3221/4885HTR3E 291/4885HTR3B 408/4885 |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | NQO1, NQO2, ABL1 | MAPK8 1826/4885HTR3E 3553/4885HTR3B 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.